Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- ChecktodayChange DetectedRevision label updated to v3.5.5, replacing the previous v3.5.4 in the page history. This indicates a new page revision was published, likely for minor editorial updates.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a small metadata update. This change does not alter the substantive content or data displayed.SummaryDifference0.1%

- Check36 days agoChange DetectedPage revision updated from v3.5.2 to v3.5.3, indicating a new build of the page. The listed change does not alter study content, eligibility criteria, or results.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to study details or page behavior.SummaryDifference0.1%

- Check86 days agoChange DetectedVersion updated from v3.4.2 to v3.4.3. No user-facing content or study details appear to be changed.SummaryDifference0.1%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.